Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors

[Image: see text] The epidermal growth factor receptor (EGFR) is genetically altered in nearly 60% of glioblastoma tumors; however, tyrosine kinase inhibitors (TKIs) against EGFR have failed to show efficacy for patients with these lethal brain tumors. This failure is attributed to the inability of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Med Chem Lett
Main Authors: Tsang, Jonathan E., Urner, Lorenz M., Kim, Gyudong, Chow, Kingsley, Baufeld, Lynn, Faull, Kym, Cloughesy, Timothy F., Clark, Peter M., Jung, Michael E., Nathanson, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2020
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549123/
https://ncbi.nlm.nih.gov/pubmed/33062157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00599
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados